7th Obesity and NASH Summit

Eli Lilly’s ‘triple G’ drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss, a new record for the obesity field has been set and the time to get ahead of the curve is now.

Time: 9:25 am – 4:00 pm

Venue details: The Westin Boston Seaport District, 425 Summer Street, Boston, Massachusetts, 02210, United States

Prices:
Drug Developer Conference + Workshop Day Ticket: USD 4946.00,
Drug Developer Conference Only: USD 2999.00,
Solution Provider Conference + Workshop Day: USD 6046.00,
Solution Provider Conference Only: USD 3799.00

Speakers: Ana Paula Cancino, Global Executive Medical Director, Obesity, Amgen, Brian Finan, Vice President, Obesity, Novo Nordisk, Cindy Hartsfield, Director, Medical Affairs, 89bio, Dong-ki Lee, Founder and Chief Executive Officer, OliX Pharmaceuticals, Erik Tillman, Associate Director, Translational Biology and Pharmacology, Akero Therapeutics, Feng Liu, Executive Director, Regor Therapeutics, Jen-Chieh (Jay) Chuang, Associate Director, Liver Diseases and Translational Biomarker Lead, Takeda, and more.